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Due to a global increase in the range and number of infections caused by multi-
resistant bacteria, phage therapy is currently experiencing a resurgence of interest.
However, there are a number of well-known concerns over the use of phages to
treat bacterial infections. In order to address concerns over safety and the poorly
understood pharmacokinetics of phages and their associated cocktails, immunological
characterization is required. In the current investigation, the immunogenicity of four
distinct phages (taken from the main families that comprise the Caudovirales order)
and their interaction with donor derived peripheral blood mononuclear cells and
immortalized cell lines (HT-29 and Caco-2 intestinal epithelial cells) were investigated
using standard immunological techniques. When exposed to high phage concentrations
(109 PFU/well), cytokine driven inflammatory responses were induced from all cell
types. Although phages appeared to inhibit the growth of intestinal epithelial cell
lines, they also appear to be non-cytotoxic. Despite co-incubation with different cell
types, phages maintained a high killing efficiency, reducing extended-spectrum beta-
lactamase-producing Escherichia coli numbers by 1–4 log10 compared to untreated
controls. When provided with a suitable bacterial host, phages were also able to actively
reproduce in the presence of human cells resulting in an approximately 2 log10 increase
in phage titer compared to the initial inoculum. Through an increased understanding
of the complex pharmacokinetics of phages, it may be possible to address some of
the safety concerns surrounding phage preparations prior to creating new therapeutic
strategies.
Keywords: pharmacokinetics, phage therapy, cytokines, immune response, multi-resistant bacteria
INTRODUCTION
Since their initial discovery, bacteriophages have been used as antibacterial agents in a number
of specialist centers in Eastern Europe. However, their initial clinical successes were later
overshadowed by the efficiency and increased use of antibiotics in Western medicine. Nonetheless,
the global spread of multi-drug resistant bacteria has revitalized research into phage biology and
its applications, as new strategies are sought to combat antibiotic resistant bacterial infections
(Kutter et al., 2010; Nilsson, 2014). Although phage therapy possesses a number of advantages
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over antibiotics, including the relative ease of isolation of new
phages compared to finding new antibiotics as well as ability to
self-replicate, concerns over efficacy and safety have also hindered
their adoption in the West for use in humans (Abedon, 2010,
2011).
In order to successfully combat a bacterial infection, phages
must first reach the site of infection in sufficiently high
concentration to be able to reproduce to an extent that
eventually all or almost all bacteria will become infected.
This requires not only high initial doses of phages but also
that the phages need to persist in the presence of, or where
possible evade, the neutralizing effect of the patients immune
system. Although initially believed to be non-immunogenic
and non-toxigenic (Adams, 1959) recent studies have shown
that high concentrations of phage can induce pro-inflammatory
responses, while long term exposure to phages could induce
an antibody response in which the spleen plays a key role in
phage clearance, which has been demonstrated to be the case
for phages T4 and T7 (Dabrowska et al., 2014; Majewska et al.,
2015; Hodyra-Stefaniak et al., 2015). Among the safety concerns
surrounding the use of phages to combat bacterial infections is
also the potential to induce toxic shock caused by the release
of lipopolysaccharide (LPS) as a result of bacterial lysis. The
injection of low doses of such endotoxins to the human body
has been shown to trigger inflammatory responses, and the
endotoxin content of pharmaceutical preparations is therefore
tightly controlled during manufacture (Merabishvili et al., 2009;
Neyen and Lemaitre, 2015). In order to be of clinical use, phage
preparations would also have to conform to varying regulatory
standards that are contingent on route of administration, prior to
approval for use.
In the current study, the cytokine response of human intestinal
epithelial cells (IEC) and immune cells to four distinct phages was
evaluated in addition to the mitogenic or cytotoxic effects of the
phages on these cells.
MATERIALS AND METHODS
All experiments in the current study were performed in triplicate
unless otherwise stated in the text.
Bacterial and Bacteriophage Culture
Escherichia coli strains (ECOR10, ECOR32, ECOR57, and
ECOR63) were obtained from the E. coli reference collection
(ECOR; Ochman and Selander, 1984), and were routinely
cultured in lysogeny broth (LB) at 37◦C with shaking at 120 RPM.
Escherichia coli phages SU10 (Podoviridae), SU32
(Siphoviridae), SU57 (Siphoviridae), and SU63 (Myoviridae)
were isolated from the Käppala Wastewater treatment works,
Lidingö, Stockholm county, Sweden, and have been characterized
elsewhere (Khan Mirzaei et al., 2014; Khan Mirzaei and Nilsson,
2015). Phages were routinely cultured in LB with appropriate
hosts (ECOR10, ECOR32, ECOR57, and ECOR63) prior to
purification in PEG-8000 and CsCl gradient centrifugation as
previously described (Villafane, 2009). Phages were enumerated
using the agar overlay method as previously described (Khan
Mirzaei and Nilsson, 2015). Extended-spectrum beta-lactamase
producing E. coli strains, here denoted ESBL-32 (strain 07RAFM-
ECO-32) and ESBL-198 (strain 07RAFM-ECO-198), were
grown in RPMI-1640 complete medium (Invitrogen, Sweden)
supplemented with 10%(v/v) heat inactivated fetal calf serum
(FCS; Invitrogen), 1%(v/v), penicillin–streptomycin (PEST;
Thermo Scientific, Logan, UT, USA), 2%(v/v) L-glutamine and
4%(v/v) HEPES (HyClone Laboratories, Inc, South Logan, UT,
USA). ESBL-198 was used for the infection of SU32, SU57, and
SU63 while ESBL-32 was used due to the limited host range of
SU10.
Preparation of Bacterial Debris
Bacterial debris was prepared from a 1.5 L overnight culture,
centrifuged at 11000 × g for 20 min and re-suspended in
20 mL of phosphate buffered saline (PBS) then sonicated
with 80% power for 15 min in a VCX130 Vibra-Cell
(Sonics & Materials Inc., Newtown, CT, USA) to break up
bacterial cells. Bacterial debris samples were subjected to CsCl
purification as previously described (Villafane, 2009). In order
to confirm the efficacy of debris removal, samples were taken
from the same point in the ultracentrifuge tube as phage
stocks.
Stimulation of HT-29 and Caco-2 Cell
Lines by Purified Bacteriophages
HT-29 (HTB-38) and Caco-2 (HTB-37) were cultured at 37◦C
in a 5% CO2 atmosphere in McCoy’s 5A (modified) medium
(ATCC or HyClone Laboratories Inc.) and in Dulbecco’s
modified Eagle’s medium (DMEM; HyClone Laboratories, Inc.),
respectively. Both media were supplemented with 10%(v/v) FCS
and 1%(v/v) PEST. To maintain exponential growth phase, cells
were treated with trypsin-EDTA (Invitrogen) and sub-cultured
before reaching confluence (Haileselassie et al., 2013).
In order to provide stimulation, HT-29 and Caco-2 cells
were trypsinated, washed in fresh medium and seeded at a final
concentration of 2 × 105 cells/well for cytokine analysis in 48
well plates (Costar, Cambridge, UK) and 5× 104 cells/well in flat-
bottomed 96-well plates (Sarstedt Inc., Newton, NC, USA) and
grown over night at 37◦C in a 5% CO2 atmosphere. Following
incubation, both Caco-2 and HT-29 cells were stimulated as
follows: (1) addition of phages alone (109 PFU/well), (2) addition
of bacteria alone (105 CFU/well), (3) simultaneous addition of
phages and the host bacteria (109 PFU/well and 105 CFU/well),
and (4) complete media only. Cells were incubated for 8 h for
cytokine analysis and 72 h for 3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide (MTT) analysis at 37◦C in 5%
CO2. Supernatants from IEC stimulations were collected and
frozen at −20◦C until cytokine analyses and the cells were
subjected to MTT analysis.
Human Cytokine Array
To profile the response of stimulated HT-29 epithelial cells, 38
cytokines were simultaneously analyzed using a Human cytokine
array kit (Cat no. ARY005, R&D Systems, Abingdon, UK)
according to the manufacturer’s instructions. Qualitative analysis
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was performed by comparing the density of the detected spots to
that of the reference spots included in the assay.
Stimulation of PBMCs by Purified
Bacteriophages
Ethical Permission
Peripheral blood mononuclear cells (PBMCs) from healthy blood
donors were obtained. The samples were treated according to
the by-law of the ethical permission granted by the Karolinska
Institute, Stockholm, Sweden (Permit no. 2014/2052-32).
PBMC Preparation
PBMC were isolated by Ficoll–Hypaque (GE Healthcare Bio-
Sciences AB, Uppsala, Sweden) gradient centrifugation and then
cyro-preserved in liquid nitrogen. Prior to use, cells were thawed
and washed three times in pre-warmed RPMI-1640 complete
medium (Invitrogen, Sweden) supplemented with 10%(v/v)
FCS, 1%(v/v) PEST, 1%(v/v) L-glutamine, and 2%(v/v) HEPES
(HyClone Laboratories, Inc.) and checked for viability. PBMC
(1 × 106 cells/mL) were then seeded into flat-bottomed 96-
well plates (Sarstedt Inc.) and co-cultured with three different
concentrations of four phages (109, 107, and 105 PFU/well)
for 24 h for cytokine analysis and a single concentration of
109 PFU/well for 96 h for MTT assay at 37◦C in a 5% CO2
atmosphere. For cytokine analysis, negative (complete media
only) and positive (50 ng/mL LPS) controls were also performed.
For MTT assays, cells treated with water and dimethyl sulfoxide
(DMSO) acted as positive controls for cell toxicity, complete
medium was used as a negative control and a-CD3/a-CD28 beads
(Invitrogen) acted as a proliferation control. Supernatants from
PBMC stimulations were collected and frozen at −20◦C until
analyzed for cytokine content and the cells were used for MTT
assay.
ELISA for Cytokine Stimulation of PBMC
ELISA was performed on purified phage preparations of
different concentrations (109, 107, and 105 PFU/well) using
commercially available kits IL-2, IL-4, IL-6, IL-10, IL-17, IFN-γ,
and TNF-α (Mabtech AB, Stockholm, Sweden) according to
the manufacturer’s instructions. Optical density (OD) was
determined at 405 nm on a micro-plate reader (Molecular
Devices Corp, Sunnyvale, CA, USA). Data were analyzed in the
SoftMax Pro 5.2 rev C software package (Molecular Devices Corp,
Sunnyvale, CA, USA).
Cell Proliferation and Toxicity Assay
Post-stimulation, 100 µL/well of their respective complete
medium containing 9.1% 12 mM MTT solution (Vybrant R© MTT
Cell Proliferation Assay Kit (Thermo Fisher Scientific, Sweden)
was added into the PBMC and IEC (Caco-2 and HT-29) culture
wells and the plates were incubated at 37◦C for 3 h. MTT solution
containing complete media was also added in an empty well
as blank control. The supernatant was then removed, and the
purple formazan crystals formed were solubilized with 50µL/well
of DMSO (Sigma-Aldrich, MO, USA). The absorbance was
determined using an automatic microplate spectrophotometer at
540 nm. The OD values for each stimulus were adjusted for the
contribution of the blank control (Peng et al., 2007).
Endotoxin Quantitation
Purified phage preparations and bacterial debris were checked
once for endotoxin content using a Pierce Limulus amebocyte
lysate (LAL) Chromogenic Endotoxin Quantitation Kit (Thermo
Fisher, Sweden) according to the manufacturer’s instructions.
Statistical Analysis
A one way ANOVA was used for the analysis of normally
distributed whole data sets, 2-tailed t-tests for pairwise
comparisons within normalized data sets, Kruskal–Wallis tests
for non-normally distributed whole data sets or Mann–
Whitney for pairwise comparisons between non-normalized
data. Statistical analysis was performed in the R Statistical
software package (R Core Team, 2015). Individual statistical tests
used are identified in the figure legends or text where necessary.
RESULTS
Phages Maintain Lytic Activity in the
Presence of Human Epithelial Cells
When incubated with epithelial cells and hosts, phages were
able to significantly reduce the bacterial content over a period
of 8 h (Figure 1A; P < 0.0001 by ANOVA). This reduction in
bacterial content was shown to be the result of productive phage
replication by an increase in phage titer over the same period
FIGURE 1 | Bactericidal activity and proliferation of phages in the
presence of human epithelial cells. (A) Bactericidal efficacy of phages in
the presence of epithelial cells. Efficacy is compared to bacteria only controls.
Solid bars are ESBL198. Hatched bars are ESBL32. (B) Active replication of
phages in the presence of host and epithelial cells; solid bars are phages and
epithelial cells only, dotted bars are phages in the presence of host and
epithelial cells. Reproduction in the presence of host is compared to phages
exposed to epithelial cells. Results from HT-29 (n = 3) and Caco-2 (n = 3)
cells were combined and data are presented as mean ± SD ∗∗∗P < 0.0001
by one way ANOVA.
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(Figure 1B; P < 0.0001 by ANOVA). It should also be noted
that all phages, were reduced in number following 8 h incubation
with epithelial cells when compared to the initial inoculum (from
5 × 105 to the lowest 3 × 105; P < 0.05 by two tailed t-test).
For SU32 this reduction was smaller (from 5 × 105 to the lowest
4 × 105; P > 0.05 by two tailed t-test). No significant impact on
the efficacy and stability of phages was observed between the two
cell lines.
Phages Activate Pro-inflammatory
Cytokines in HT-29 Cells
When phages were incubated with HT-29 cells in the absence of
a suitable host, cytokines IL-8, CXCL-1/GROα and Macrophage
migration inhibitory factor (MIF) were induced (Table 1). In the
presence of a bacterial host (ESBL-198), a more intense pattern
of cytokine activation was observed for phages SU32, SU57, and
SU63. An additional cytokine, IL-1ra/IL-1F3 was activated in the
presence of ESBL-198 only.
Due to the host range of SU10, a second ESBL containing
E. coli (ESBL-32) was chosen for comparative analysis. This
combination of phage and host induced an additional pair of
cytokines, IL-18/IL-1F4 and IL-1ra/IL-1F3 in the presence of HT-
29 cells (Table 1). These additional cytokines were also present in
the ESBL-32 control.
Inflammatory and Anti-inflammatory
Immune Response Varies between
Phages
When assessed at the highest phage concentration (109 PFU/well)
all samples were found to induce IL-6, IL-10, and TNF-α
(Figure 2) at varying levels depending on the phage/cytokine
combination. When compared to the medium (negative) control,
IL-6 was significantly induced by all phages (P< 0.002 by Mann–
Whitney) with the exception of SU32. Both IL-10 and TNF-α
were significantly induced by SU57 and SU63 (P < 0.05 by
Mann–Whitney) but not by SU10 or SU32 when compared to the
negative control. When compared to the positive (LPS) control,
all phages were significantly less immunostimulatory (P< 0.05 by
Mann–Whitney) with the exception of SU63. TNF-α induction
levels for SU57 were insignificant when compared to LPS. When
comparing the ratio of TNF-α to IL-10, phage treated samples
were higher than the medium control (P > 0.05 by Mann–
Whitney). At lower phage concentrations (107 and 105 PFU/well)
no significant induction of cytokines were observed (data not
shown). IFN-γ was induced by all four phages but only in PBMCs
obtained from two donors. The levels of IL-2, IL-4, and IL-
17 were below the limit of detection for all conditions tested.
In addition, no response to the purified bacterial debris when
incubated with PBMC was observed (data not shown).
Phages Are Non-toxic to Human Cells
In a long term assessment of the cytotoxic effects of individual
phages on IECs and PBMCs, phages at a concentration of 109
PFU/well were not lethal to the HT-29 and Caco-2 cells after 96 h
of incubation (P < 0.05 by two tailed t-test) and no significant
differences between the cell lines were observed (Figure 3). Phage
stimulated IECs produced a significantly (P < 0.05 by two tailed
t-test) higher OD response compared to the negative control.
Phages were unable to induce a significant cytotoxic effect on
PBMCs.
LAL Analysis of Phage Preparations May
Not Be Suitable for Quality Control
Purposes
Phage preparations at the highest concentrations (109 PFU/mL)
showed marked differences in endotoxin content compared to the
bacterial debris control.
DISCUSSION
Phage therapy has enjoyed renewed interest for the treatment of
multi-drug resistant bacteria due to increasing global levels of
resistance. Despite this renewed interest, a number of concerns
still exist over their safety and efficacy, which require substantial
investigation. Depending on the route of administration, phages
would require a level of persistence in the presence of, or
the ability to evade, innate and adaptive immune components
in order to reach a target site and produce a therapeutic
TABLE 1 | Cytokine release from HT-29 cells when exposed to four structurally distinct phages.
Cytokine Bacteriophage Bacteria and phage Controls
SU10 SU32 SU57 SU63 ESBL-198 ESBL-32 ESBL-198 ESBL-32 Medium
SU32 SU57 SU63 SU10
IL-8 ++ + + + ++ +++ +++ ++ +++ +++ −
IL-18/IL-1F4 − − − − − − − ++ − ++ −
CXCL1/ GROα ++ + + + ++ ++ +++ ++ ++ ++ −
IL-1ra/IL-1F3 − − − − − − − +++ ++ +++ −
MIF + ++ ++ ++ ++ ++ ++ +++ +++ +++ ++
+++Pixel intensity ≥ reference spot.
++Pixel intensity < reference spot.
+Pixel intensity < than reference and test (bacteria and phage) spots.
−No response detected.
Frontiers in Microbiology | www.frontiersin.org 4 March 2016 | Volume 7 | Article 437
fmicb-07-00437 March 28, 2016 Time: 12:49 # 5
Khan Mirzaei et al. Phage Immunogenicity to Human Cells
FIGURE 2 | Cytokine release by peripheral blood mononuclear cells (PBMCs) following exposure to high concentrations (109 PFU/well) of four
different purified bacteriophages. (A) IL-10 release. (B) IL-6 release. (C) TNF-α release. Data are the mean of two replicates taken from six donors ± SD.
∗∗P < 0.001; ∗P < 0.05 by Mann–Whitney. Cytokine induction by phages is compared to medium.
FIGURE 3 | Cell cytotoxicity and inhibition of proliferation by exposure to phages. (A) Phage exposure to intestinal epithelial cells; HT-29 (n = 4)  and
Caco-2 (n = 4) . Data are presented as the mean ± SD. ∗P < 0.05 by two tailed t-test compared to the medium control. (B) Phage exposure of PBMCs. Data are
from two replicates from four donors.
effect (Abedon, 2011; Chan and Abedon, 2012). In the current
study, all phages were shown to maintain killing efficacy and
replicative ability in the presence of IECs and a suitable bacterial
host. However, individual phages varied in their ability to
elicit an immunogenic response with SU57 (Siphoviridae) and
SU63 (Myoviridae) being the most immunogenic and SU32
(Siphoviridae) the least and suggests that phage immunogenicity
cannot be generalized between families (e.g., SU57, SU63)
or within the same family (e.g., SU32 and SU57). Despite
the temptation to generalize the immunogenic properties of
phages, recent studies have demonstrated that different proteins
within the T4 phage possess different levels of immunogenicity
(Dabrowska et al., 2014; Majewska et al., 2015). In order to
ascertain the differences in immunogenicity between phage
families (e.g., Myoviridae, Siphoviridae, or Podoviridae) or
individual phages (e.g., SU63 and SU32 in the current work),
comparisons between protein content and tertiary structures
would be required.
Impact on Phage Efficacy and Viability
When Exposed to Human Epithelial Cells
In order to be a viable adjuvant or alternative to conventional
antibiotic therapy, whole phage therapeutics requires the
establishment of a productive infection lifecycle. Following
administration, this would require the migration of phages to the
site of bacterial infection and the ability to persist in the presence
of, or evade, the immune system while maintaining an infectious
dose (Abedon and Thomas-Abedon, 2010; Abedon, 2011; Bull
and Gill, 2014). ESBL-32 was chosen as a specific host for SU10
Frontiers in Microbiology | www.frontiersin.org 5 March 2016 | Volume 7 | Article 437
fmicb-07-00437 March 28, 2016 Time: 12:49 # 6
Khan Mirzaei et al. Phage Immunogenicity to Human Cells
for the current investigation in order to produce comparable
levels of activity between the four phages (Khan Mirzaei and
Nilsson, 2015). Despite the maintenance of high killing efficacy
and reproductive ability in the presence of IECs and suitable
bacterial hosts (Figure 1), the number of phages reduced with a
different level in the absence of bacterial hosts compared to the
initial inoculum which could be due to difference in their stability
under the experimental conditions. However, this low level of
clearance would not explain the disparity between the activities of
different phages, i.e., approximately 2–3 log10 difference between
SU10 and the other phages and may result from the unique
infection dynamics of each phage (Bull et al., 2014). Although
not considered in this study, the in situ environmental conditions
(e.g., gut pH) may potentially have a detrimental effect on the
stability and efficacy of the phages.
Cytokine Release and Immune
Stimulation Following Phage Exposure
The current study shows the varying degrees of immunogenicity
exhibited by four distinct phages of the Caudovirales order
when stimulating human PBMCs and IECs. IL-18 activation is
of current interest as a vaccine adjuvant due to the ability to
activate T-cells in the presence of different bacteria and cell types
(Miettinen et al., 1998; Sugimoto et al., 2004). It is generally
believed that phages are safe for human use, however, the lack
of appropriate clinical trials and a lack of regulatory approval
have restricted routine clinical use to specialist centers around the
world (Skurnik and Strauch, 2006; Sarker et al., 2012). However,
the current investigation suggests that both SU57 and SU63 at
high concentrations (109 PFU/well) can significantly induce IL-
6 and TNF-α from PBMCs compared to the negative (medium)
control. SU57 and SU63 were also able to significantly induce
the anti-inflammatory cytokine IL-10 compared to the negative
(medium) control. In addition to this, SU10 also activates IL-
6 release with a significant level from PBMCs compared to the
negative (medium) control. Despite a lack of toxicity in both HT-
29 and Caco-2 cells, phage exposure inhibited cell proliferation
via an unknown mechanism although there is some suggestion
that the interaction between phages and epithelial cells may result
in the rapid release of reactive oxygen species (Gorski et al., 2012).
Endotoxin Determination in Phage
Preparations
In order to satisfy regulatory requirements for non-topical
clinical application, particularly intravenous injection, it is
necessary to quantify endotoxin levels in the final product
(Merabishvili et al., 2009). This is routinely accomplished with
the “gold standard” method of an LAL assay. However, a
number of studies suggest that the use of LAL assays results
in ambiguous results when applied on phages (Merabishvili
et al., 2009; Cooper et al., 2014) and was again highlighted in
the current study. This discrepancy between LAL results and
immune response studies may be the result of phages/LAL cross
reactivity. Although supplemental methods, including in vivo
assessments exist, these methods may not provide the required
level of sensitivity necessary for pharmaceutical quality control
and also raise ethical concerns over routine animal usage. An
ELISA assay to profile immune responses to formulations may
provide a sensitive alternative to LAL assessment and address
ethical concerns over routine animal usage as has been suggested
by Hodyra-Stefaniak et al. (2015) and should be the focus of
future work.
CONCLUSION
The level of immunogenicity varies between the phages tested
with SU57 and SU63 stimulating a greater release of IL-10, IL-
6, and TNF-α compared to SU10 and SU32 in PBMCs. Despite
this immunostimulatory activity, all phages were able to maintain
high levels of lytic activity and establish reproductive cycles in the
presence of suitable bacterial hosts and IECs. This may suggest
that should sufficient numbers of phages reach a site of infection
then a therapeutic effect may arise. All phages halted the growth
rate of IECs compared to the control medium. The current
investigation has highlighted the importance of immunological
studies for the development of phages for use in human therapy
and also that cell line studies may provide an additional method
for endotoxin detection and quantification.
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